Tadeusz Kubicki

6PUBLICATIONS
35CO-AUTHORS
Haematological tumoursMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 16, 2025
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.

Jennifer H Cooperrider, Diren Arda Karaoglu, Tadeusz Kubicki

|Oct 07, 2024
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).

Benjamin A Derman, Ajay Major, Jennifer Cooperrider

|May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.

Benjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt

|May 07, 2024
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Tadeusz Kubicki, Dominik Dytfeld, David Barnidge

|Sep 10, 2023
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.

Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel

|Feb 10, 2021
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

Benjamin A Derman, Andrew T Stefka, Ken Jiang

Pageof 1

Frequent Collaborators

4 joint publications

Benjamin A Derman

4 joint publications

Andrzej Jakubowiak

2 joint publications

Andrew T Stefka

2 joint publications

Łukasz Szukalski